Surveillance of Extended-Spectrum \(\beta\)-Lactamase-, Cephalosporinase- and Carbapenemase-Producing Gram-Negative Bacteria in Raw Milk Filters and Healthy Dairy Cattle in Three Farms in Île-de-France, France

Vincent Plassard*†, Philippe Gisbert‡, Sophie A. Granier³ and Yves Millemann¹,⁴

¹ Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France, ‡ Ceva Santé Animale, Libourne, France, ³ Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail, Fougères, France, ⁴ Laboratoire de Sécurité des Aliments de l’ANSES, Maisons-Alfort, France

The aim of this work was to test a surveillance protocol able to detect extended-spectrum \(\beta\)-lactamase (ESBL)-, cephalosporinase (AmpC)- and carbapenemase (CP)-producing gram-negative bacteria in three conveniently chosen dairy farms with known prior occurrences of ESBL- and CP-producing strains. The protocol was applied monthly for a year. At each visit, 10 healthy lactating dairy cows were rectally swabbed, and raw milk filters (RMFs) were sampled in two of the three farms. Bacterial isolation was based on a first screening step with MacConkey agar supplemented with 1 mg/L cefotaxime and commercial carbapenem-supplemented media. We failed to detect CP-producing strains but showed that ESBL- \textit{Escherichia} strains, found in one farm only (13 strains), were closely associated with multi-drug resistance (12 out of 13). The limited number of conveniently selected farms and the fact that RMFs could not be retrieved from one of them limit the validity of our findings. Still, our results illustrate that ESBL-status changes monthly based on fecal swabs and negative herds should be qualified as "unsuspected" as proposed by previous authors. Although surveillance of farm statuses based on RMF analysis could theoretically allow for a better sensitivity than individual swabs, we failed to illustrate it as both farms where RMFs could be retrieved were constantly negative. Determination of CP herd-level status based on RMFs and our surveillance protocol was hindered by the presence of intrinsically resistant bacteria or strains cumulating multiple non-CP resistance mechanisms which means our protocol is not specific enough for routine monitoring of CP in dairy farms.

Keywords: antimicrobial resistance, carbapenemase, extended-spectrum beta-lactamase, multi-drug resistance, dairy cattle, gram-negative
INTRODUCTION

Extended-spectrum β-lactam (ESBL)-, cephalosporinase (AmpC)- and carbapenemase (CP)-producing gram-negative (GN) bacteria have been described in numerous settings of the ecosphere worldwide (1), including cattle (2, 3). An increasing amount of evidence of gut colonization in cattle with ESBL-/AmpC- (4–7) and CP-producing GN bacteria (8, 9) is accruing, especially in commensal Enterobacteriaceae, among healthy beef cattle (10, 11) and healthy dairy cattle (8, 12–16). ESBL-/AmpC-/CP-producing GN bacteria have also been reported in raw milk (17, 18). In the One Health approach the presence of these bacteria in livestock such as cattle creates a general concern of the scientific community who sees the animal sector as a reservoir for selection and amplification of antimicrobial resistance genes by the use of antibiotics before they eventually spread back to humans (1). Data gaps still exist which prevent a full quantitative risk analysis of possible transmission routes through livestock to humans, e.g., levels of ESBL-producing Escherichia coli in the bulk tank milk (BTM) on farm (19) and CP-reports using systematic screening with carbapenem-supplemented selective media instead of side investigations within other studies (1).

Indeed, only a few studies actually address the presence of nonpathogenic or commensal antimicrobial resistant bacteria specifically in BTM as a main research project (20–22), most of them being focused on the detection and antimicrobial profiling of zoonotic foodborne pathogens [e.g., (23–26)]. Instead of BTM, or concomitantly with BTM, some authors advocate the analysis of raw milk-filters (RMFs) as a way to monitor the presence of zoonotic foodborne pathogens in a dairy herd (27) or in raw milk (23, 28–31). In-line RMFs are an essential part of milking systems, trapping particles of organic material and foreign objects, but they are not designed to ward off bacteria. Residues withheld in the RMFs are considered as real-time indicators of the fecal shedding of zoonotic pathogens from a milking herd and its environment (27, 30) or indicators of the presence of resistant commensal E. coli in dairy herds (32–34). Overall, these studies illustrate the usefulness of RMF analysis as a way to monitor the presence of both zoonotic foodborne pathogens and commensal antimicrobial resistant bacteria in dairy herds.

Therefore, we conducted a longitudinal study focused on monitoring the presence of ESBL-/AmpC-/CP-producing GN bacteria in three dairy farms by using RMF as a proxy for dairy cows fecal shedding of resistant GN enteric bacteria. RMF analysis was associated with concomitant fecal samplings of healthy lactating dairy cattle in order to assess the baseline of resistant GN enteric bacteria in dairy cows in each farm. The objective of this study was to devise and test this surveillance protocol which would allow repeated point-of-care diagnostics able to detect the presence of ESBL-/AmpC-/CP-producing GN bacteria at the dairy farm level.

MATERIALS AND METHODS

Herd Selection and Farm Visits

Three suburban conventional dairy farms (i.e., non-organic) were selected, all located in the same department at the South-West of Paris. During the year 2018, the mean number of lactating cows was 393 in Farm A, 168 in Farm B and 150 in Farm C. This choice was a convenient one as these farms are regularly visited for routine reproductive follow-ups by members of our teaching team. Besides, these farms had already been included in previous studies conducted by members of our research team which demonstrated the intestinal colonization of cows in Farm A by CP-producing Acinetobacter in 2010 (9), and the intestinal colonization of cows in Farms A and B by ESBL-producing E. coli in 2015 (35). The study lasted 1 year, from January 2018 to December 2018; samplings were scheduled once a month in each farm.

Cow Selection

At each sampling session, a convenient number of ten cows were randomly selected among the 40–90 cows presented for a routine reproductive follow-up using random number generator from Excel (Microsoft Corporation, version 2013). Reasons for their inclusion in routine reproductive follow-up were uterine involution control, pregnancy diagnosis at 1, 3, or 7 months, and anestrus. To be included in the study, a cow needed to be clinically healthy after clinical examination by the first author, and its milk had to be currently collected. Characteristics of sample populations in each farm are presented in Supplementary Table 1.

Samples Collection

Rectal swabs were performed using a swab with Amies agar (Copan, Brescia, Italy). RMFs were collected at the end of the morning milking session, before the cleaning and rinse procedures, and placed in a sterile plastic stomacher bag (Fisher Scientific, Illkirch, France) then sealed. Only Farm B and Farm C used milk filters, Farm A used a percolation system to trap debris which unfortunately prevented the addition of a filter. This information wasn’t mentioned by the farm manager at enrollment. All samples were stored on ice and delivered to the laboratory within 4 h from collection. Once arrived in the laboratory, the samples were immediately processed.

Laboratory Screening Procedures

Swabs were placed aseptically in 9 mL buffered peptone water (BPW) (bioMérieux, Marcy l’Etoile, France). RMFs were unsealed, kept in the stomacher bag, soaked with 225 mL of BPW (bioMérieux, Marcy l’Etoile, France) and sealed again. The stomacher bag was then shaken manually. All samples were incubated at 37 ± 2°C for 4–6 h for pre-enrichment. Antimicrobial resistant isolates were sought with three different selective media: ChromID™ CARBA (bioMérieux, Marcy l’Etoile, France), ChromID™ OXA-48 (bioMérieux, Marcy l’Etoile, France) and a non-commercial selective MacConkey (McC) agar plate (Gondalab, Madrid, Spain) supplemented with 1 mg/L cefotaxime (COX) (Sigma-Aldrich, Saint-Louis, MO, USA). Quality of the latter media was controlled before each use with a negative strain E. coli ATCC25922 and a positive strain E. coli NCTC13353. Plates were inoculated with 10 μL of enriched solution, placed at 37 ± 2°C for 18–24 h for a first reading, and then replaced at 37 ± 2°C for another 18–24 h for a second reading. At the last reading, phenotypically different and isolated
colonies were numbered and smeared on the corresponding media then incubated for another 24 h at 37 ± 2°C. Once purity was confirmed, a colony was taken and stored at −80°C using cryo-beads (bioMérieux, Marcy l’Etoile, France).

**Microbial Identification**

Phenotypically resistant strains were identified to the genus- and species-level using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Isolates were processed on a Biotyper Microflex LT® using Flex Control software (Bruker Daltonics, Champs-sur-Marne, France). The MALDI-TOF target plate was prepared using the extraction method given by the manufacturer. Species identification cut-off values were applied according to the manufacturer’s instructions, according to which a score of ≥2 indicated a species-level identification, a score between ≥1.7 and <2 indicated a genus-level identification. Whatever the isolate, a score <1.7 was considered inconclusive. In that case, the sample was cultured again on a brain heart infusion agar at 37 ± 2°C for reprocessing the next day. Failure to obtain at least an identification to the genus-level prompted an exclusion from further analysis.

Non-GN isolates and intrinsically resistant GN isolates were excluded from further analysis. Briefly, **Pseudomonas** spp. (36), **Acinetobacter** spp. (36–38), **Achromobacter** spp. (39), **Wautersiella falsenii** (40), and **Empedobacter brevis** (41) were considered naturally resistant to COX; **Stenotrophomonas maltophilia** (36) and **Arcobacter butzleri** (42) were considered naturally resistant to carbapenems.

**Antimicrobial Susceptibility Testing**

All GN isolates for which growth on McC-COX, ChromID™ CARBA or ChromID™ OXA-48 could not be attributed to intrinsically resistance to COX or carbapenems were submitted to antimicrobial susceptibility testing (AST) by disc diffusion with a panel of 15 antimicrobial agents (Supplementary Table 2) on Mueller-Hinton agar (bioMérieux, Marcy l’Etoile, France). The EUCAST standards were followed for inoculum standardization and incubation conditions (43). Quality control was performed using *E. coli* ATCC25922 (44). Antimicrobial disks (Biorad, Marnes-la-Coquette, France) were spaced by a standard distance of 30 mm from each other. Inhibition zone diameter (IZD) readings were made following EUCAST recommendations (45); results are available for all strains as supplemental material (Supplementary Table 3). When available, EUCAST epidemiological cut-off values (ECOFF) were applied to determine “microbiological” resistance (46), otherwise EUCAST clinical breakpoints were used (43) (Supplementary Table 2).

Of note, neither the ECOFF nor the clinical breakpoint for tetracycline (TET) for **Enterobacteriaceae** being available in the EUCAST database, the 2018 CLSI clinical breakpoint was applied for this antimicrobial agent after verification that incubation methods were compatible (47). Antimicrobial resistance patterns for each strain constituted the basis for determining duplicates originating from the same samples, i.e., bacteria of the same genus and species isolated from the same matrix on the same media and on the same day. Duplicates were excluded from final data presentation.

This panel was a compromise intended to allow both detection of ESBL-/AmpC-/CP-phenotypes and assessment of multi-drug resistance (MDR) among **Enterobacteriaceae** and **Pseudomonads** which were the most frequently identified families. The panel allowed: (i) screening of *E. coli* strains stably overproducing AmpC β-lactamase by applying a breakpoint of <19 mm for cefoxitin (FOX) (43); (ii) detection of inducible-AmpC production among **Enterobacteriaceae** and **Pseudomonas** spp. by performing a Ceftazidime-Imipenem Antagonism Test (CIAT) (48); (iii) detection of ESBL-producing **Enterobacteriaceae** strains by performing three double-disk synergy tests [DDSTs; amoxicillin-clavulanic acid (AMC) next to COX, ceftazidime (CZD) and cefepime (FEP)] (49); (iv) detection of a subsample of potentially CP-producing strains among ChromID™ CARBA and ChromID™ OXA-48 isolates based on imipenem (IPM) EUCAST ECOFF when available, EUCAST clinical breakpoint otherwise. This subsample of IPM-resistant strains was subsequently tested for CP production by using a commercial RAPIDEC® CARBA NP test (bioMérieux, Marcy l’Etoile, France); (v) definition of MDR status, i.e., “microbiological” resistance to three or more antimicrobial classes (46, 50).

The algorithm used for determining the isolates’ ESBL-/AmpC-/CP-statuses is summarized in Supplementary Figure 1.

**Definition of ESBL/AmpC/CP Herd Status**

Herd status were defined as positive, following the terminology used by previous authors (12, 51), negative herds were defined as unsuspected.

**RESULTS**

**Farm Characteristics and Sample Descriptions**

Farms A and B were visited 11 times during the year 2018, Farm C 12 times, with a mean number of 32 days between visits in Farms A and B, and 29 days in Farm C. Overall, 338 rectal swabs were performed, with 110 animals sampled in Farms A and B, and 118 in Farm C; 23 RMFs were sampled in Farms B and C, with, respectively, 11 and 12 RMFs for each farm. Two rectal swabs were excluded in Farm C at the December visit because of an identification error. The median cow characteristics at the day of sampling are presented in Supplementary Table 1. As sampled cows were randomly selected among cows presented for reproductive motives, some animals were sampled multiple times during the year 2018: 12, 20, and 28 cows were therefore sampled at least two times in Farms A, B, and C, respectively.

**Microbial Identification and Frequency of Genera and Species**

In Farm A, 72 isolates were submitted to identification. Using MALDI-TOF, a total of 62 (86%) isolates from fecal swabs were identified at least to the genus-level. Non-GN organisms were predominantly isolated (41 isolates, 57%), especially **Candida** spp. which represented 29 of the 72 isolates (40%). The second most predominant genus in Farm A was **Escherichia** spp. which
represented 13 out of the 72 isolates (18%). Within the 13 *Escherichia* spp., five were identified to the species-level as *E. coli*.

In Farm B, 20 isolates of fecal swab origin were submitted to identification and all of them were identified at least to the genus-level. Again, non-GN organisms were dominant (13 isolates, 65%), especially *Candida* spp. which represented 12 of the 20 isolates (60%). Ninety-one isolates of RMF origin were submitted to identification, and 71 (88%) were identified at least to the genus-level. Contrary to fecal swab isolates, non-GN organisms were scarcely isolated in RMF (two out of 81, 2%).

The most predominant genus was *Pseudomonas* spp., two of which were lactose-negative on McC CARBA and ChromID TM. Among the 97 strains of RMF origin identified to the genus-level, 38 were submitted to AST (Table 2): 21 *Pseudomonas* spp., 12 *P. aeruginosa*, two *Pseudomonas koreensis*, one *Pseudomonas mendocina*, one *Acinetobacter proteolyticus*, and one *Aeromonas hydrophila*. All of these strains were isolated on ChromID TM CARBA or ChromID TM OXA-48 media. *Pseudomonas* spp. and 11 *Pseudomonas aeruginosa* were resistant to IPM, none of them were MDR. All the other isolates, including *Aeromonas hydrophila* and *A. proteolyticus*, were pansusceptible. All the *Pseudomonas* spp. and *P. aeruginosa* IPM-resistant strains and one *P. aeruginosa* IPM-susceptible strain were inducible AmpC-producers based on the CIAT. The subsample of 14 IPM-resistant *Pseudomonas* spp. isolated from RMFs were submitted to a commercial RAPIDEC® CARBA NP test: none were positive (Table 3). Screening results being consistently negative for both rectal swabs and RMFs at every sampling period, Farm B was classified as ESBL- and CP-unsuspected.

In Farm C, out of the 29 isolates of fecal origin identified to the genus-level, only one was submitted to AST (Table 2): an *E. coli* isolated from ChromID™ CARBA in May, which was pansusceptible, ESBL-/AmpC- and CIAT-negative. Out of the 97 strains of RMF origin identified to the genus-level, 46 were submitted to AST: 27 *Pseudomonas* spp., nine *P. aeruginosa*, one *P. mendocina*, four *Pseudomonas nitroreducens*, two *Aeromonas* spp., two *Aeromonas veronii* and one *Aeromonas hydrophila*. All these strains were isolated from ChromID™ CARBA and ChromID™ OXA-48. Only three *P. aeruginosa* isolated in March and May were resistant to IPM, none of them were MDR. The RAPIDEC® CARBA NP tests were negative for the IPM-resistant *P. aeruginosa* strains (Table 3). Screening results being consistently negative for both rectal swabs and RMFs at every sampling period, Farm C was classified as ESBL- and CP-unsuspected.

**DISCUSSION**

Herd’s statuses were assessed monthly by analyzing fecal swabs from healthy lactating dairy cows in all farms, and by analyzing RMFs in two of the three farms. When assessing the data, it should be understood the classification of isolates as being ESBL-/AmpC-/CP-positive or negative is based on their phenotype and would require further testing, especially to confirm the mobile nature of the resistance genes in ESBL-positive isolates.
### TABLE 1 | Number (percent) of each genera identified among isolates of fecal swab or raw milk filter origin within each farm over the year 2018.

#### Isolates of fecal swab origin

| Genus                  | Farm A no. (%; n = 72) | Farm B no. (%; n = 20) | Farm C no. (%; n = 35) | Total (%; n = 127) |
|------------------------|------------------------|------------------------|------------------------|---------------------|
|                        | McC + COX | CARBA | OXA-48 | Total  | McC + COX | CARBA | OXA-48 | Total  | McC + COX | CARBA | OXA-48 | Total  |
| Inconclusive^a          |           |       |        |        | 2 (3%)   | 8 (11%) | 10 (14%) |        | 2 (6%)   | 4 (12%) | 6 (17%) | 1 (3%) |
| Non-gram-negative^b     | 13 (18%)  | 28 (39%) | 41 (57%) | 3 (15%) | 10 (50%) | 13 (65%) | 0 (0%) | 28 (80%) | 28 (80%) | 82 (65%) | 16 (13%) |
| Candida spp.^c          | 8 (11%)   | 21 (29%) | 29 (40%) | 2 (10%) | 0 (0%)  | 2 (10%) | 0 (0%)    | 26 (74%) | 26 (74%) | 67 (53%) |
| Gram-negative           | 16 (22%)  | 5 (7%) | 21 (29%) | 4 (20%) | 3 (15%) | 7 (35%) | 0 (0%) | 4 (12%) | 4 (12%) | 29 (23%) |
| Acinetobacter spp.      | 0 (0%)    | 0 (0%) | 0 (0%) | 2 (10%) | 0 (0%) | 2 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (2%) |
| Bordetella spp.         | 0 (0%)    | 0 (0%) | 0 (0%) | 1 (5%) | 0 (0%) | 1 (5%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (<1%) |
| Enterobacter spp.       | 0 (0%)    | 2 (3%) | 2 (3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (2%) |
| Ochrobactrum spp.       | 0 (0%)    | 0 (0%) | 0 (0%) | 0 (0%) | 2 (10%) | 2 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (2%) |
| Escherichia spp.        | 13 (18%)  | 0 (0%) | 13 (18%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 14 (11%) |
| Including E. coli       | 5 (7%)    | 0 (0%) | 5 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 6 (5%) |
| Pseudomonas spp.        | 3 (4%)    | 3 (4%) | 6 (8%) | 1 (5%) | 1 (5%) | 2 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | 8 (6%) |
| Including P. aeruginosa| 1 (1%)    | 0 (0%) | 0 (0%) | 0 (0%) | 1 (5%) | 1 (5%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (2%) |
| Total                   | 31 (43%)  | 41 (57%) | 72 (100%) | 7 (35%) | 13 (65%) | 20 (100%) | 2 (6%) | 33 (94%) | 35 (100%) | 127 (100%) |

#### Isolates of raw milk filter origin

| Genus                  | Farm B no. (%; n = 81) | Farm C no. (%; n = 114) | Total (%; n = 195) |
|------------------------|------------------------|------------------------|---------------------|
|                        | McC + COX | CARBA | OXA-48 | Total  | McC + COX | CARBA | OXA-48 | Total  | McC + COX | CARBA | OXA-48 | Total  |
| Inconclusive^a          |           |       |        |        | 5 (6%)   | 5 (6%) | 10 (12%) |        | 4 (4%)   | 13 (11%) | 17 (15%) | 27 (14%) |
| Non-gram-negative^b     | 0 (0%)    | 2 (2%) | 2 (2%) | 0 (0%) | 1 (1%) | 1 (1%) | 1 (1%) | 3 (2%) |
| Gram-negative           | 25 (31%)  | 44 (55%) | 69 (85%) | 34 (30%) | 62 (54%) | 96 (84%) | 165 (85%) |
| Achromobacter spp.      | 0 (0%)    | 0 (0%) | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) |
| Acinetobacter spp.      | 3 (4%)    | 1 (1%) | 4 (5%) | 5 (4%) | 0 (0%) | 5 (4%) | 5 (4%) |
| Aeromonas spp.          | 0 (0%)    | 1 (1%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Arcobacter spp.         | 0 (0%)    | 0 (0%) | 0 (0%) | 0 (0%) | 2 (2%) | 2 (2%) | 2 (2%) |
| Empedobacter spp.       | 0 (0%)    | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | 1 (1%) | 1 (1%) |
| Myroides spp.           | 0 (0%)    | 0 (0%) | 0 (0%) | 0 (0%) | 3 (3%) | 3 (3%) | 3 (3%) |
| Ochrobactrum spp.       | 0 (0%)    | 1 (1%) | 1 (1%) | 0 (0%) | 1 (1%) | 1 (1%) | 1 (1%) |
| Stenotrophomonas spp.   | 0 (0%)    | 5 (6%) | 5 (6%) | 0 (0%) | 9 (8%) | 9 (8%) | 14 (7%) |
| Wautersiella spp.       | 1 (1%)    | 0 (0%) | 1 (1%) | 3 (3%) | 0 (0%) | 3 (3%) | 4 (2%) |
| Pseudomonas spp.        | 21 (26%)  | 36 (44%) | 57 (70%) | 24 (21%) | 41 (38%) | 65 (57%) | 122 (63%) |
| Including P. aeruginosa| 12 (15%)  | 12 (15%) | 24 (30%) | 14 (12%) | 9 (8%) | 23 (20%) | 47 (24%) |
| Total                   | 30 (37%)  | 51 (63%) | 81 (100%) | 38 (33%) | 66 (67%) | 114 (100%) | 195 (100%) |

^a Isolates for which MALDI-TOF score was < 1.7.
^b Isolates for which MALDI-TOF score was > 1.7 and < 2.
^c Isolates for which MALDI-TOF score was > 2.

The farms had been selected partly because there were previous occurrences of ESBL-producing *Enterobacteriaceae* in Farms A and B, and because a CP-producing *Acinetobacter* was isolated in Farm A (9) and yet we failed to isolate any CP-producing strain and found ESBL-producing *Escherichia* only in Farm A. This contradiction with previous results might be due to...
TABLE 2 | Occurrence of resistance to cefotaxime and imipenem in gram-negative bacteria isolated, respectively, on McC, and ChromID TM.

| Strains isolated on | Total no. of isolates | No. of isolates identified to genus-level (OXA-48, in each farm in 2018. | No. of isolates submitted to AST (%) | No. of isolates identified to genus-level (COX-resistant, in each farm in 2018. | No. of isolates submitted to AST (%) | No. of isolates identified to genus-level (IPM-resistant, in each farm in 2018. | No. of isolates submitted to AST (%) |
|---------------------|-----------------------|-------------------------------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|----------------------------------|
| Fecal swabs         |                       |                                                                   |                                     |                                     |                                     |                                     |                                  |
| Farm A              | 31                    | 29 (94%)                                                          | 0 (0%)                              | 13 (42%)                           | 13 (42%)                           | 4 (13%)                            | 0 (0%)                           |
| Farm B              | 7                     | 7 (100%)                                                          | 0 (0%)                              | 0 (0%)                             | 0 (0%)                             | 0 (0%)                             | 0 (0%)                           |
| Farm C              | 2                     | 0 (0%)                                                            | 0 (0%)                              | 0 (0%)                             | 0 (0%)                             | 0 (0%)                             | 0 (0%)                           |
| Total               | 40                    | 36 (90%)                                                          | 13 (36%)                            | 13 (36%)                           | 7 (18%)                            | 4 (10%)                            | 0 (0%)                           |
| Raw milk filters    |                       |                                                                   |                                     |                                     |                                     |                                     |                                  |
| Farm B              | 30                    | 25 (83%)                                                          | 0 (0%)                              | 0 (0%)                             | 0 (0%)                             | 0 (0%)                             | 0 (0%)                           |
| Total               | 71                    | 62 (87%)                                                          | 13 (19%)                            | 13 (19%)                           | 10 (14%)                           | 6 (8%)                             | 0 (0%)                           |

Percentages are based on the total number of isolates in respective farms.

a Number of isolates identified to the genus-level on selective media.

b Number of isolates identified to the genus-level at least to the level of MALDI-TOF.

c Number of isolates identified to the genus-level at least to the level of MALDI-TOF or carbapenem-supplemented agars.

d Number of isolates identified to the genus-level after exclusion of isolates intrinsically resistant to COX or carbapenems based on genus and/or species.

The number of isolates identified to the genus-level after exclusion of duplicate strains based on antimicrobial susceptibility profiles.

To the best of our knowledge, only a handful of studies have reported the use of carbapenem agars as an initial screening step with the objective of detecting CP-producing GN bacteria in the gut of healthy cattle (11, 52) or in milk from healthy cattle (53). In our study, screening with commercial carbapenem agars led to the isolation of mainly *Pseudomonas* spp., *Ochrobactrum* spp. and *Enterobacter* spp. from fecal swabs, and of *Pseudomonas* spp., *Ochrobactrum* spp., *Acrononas* spp., *Arcobacter* spp. and *Stenotrophomonas* spp. from RMFs. These results are consistent with the previous studies in which the main genera identified are mentioned (11, 53). In all these reports, as well as in ours, no CP production or CP-genes were evidenced despite the isolation of numerous GN strains on commercial carbapenem-supplemented agars, illustrating the overall poor specificity of these media for CP-producing strain detection when applied to cattle or raw milk compared to monitoring in human patients (54–56). At least two hypotheses can be advanced to explain this poor apparent specificity: (i) evaluation studies of commercial carbapenem-supplemented agars in humans are often performed in regions where patients are frequently colonized with CP-producing bacteria, and in populations with scarcely detected CP-producing bacteria such as cattle, screening with commercial agars are expected to exhibit lower predictive positive value (56); (ii) commensal GN bacteria isolated from cattle or raw
TABLE 3 | Summary of presumptive ESBL-/AmpC-/CP-producing Escherichia spp. and Pseudomonas spp. collected within the monitoring in 2018.

| Matrix | Farm | Selective media | No. of presumptive ESBL producers (%)b | No. of presumptive AmpC producers (%) | No. of presumptive CP producers (%)d | No. of MDR isolates (%)e |
|--------|------|-----------------|--------------------------------------|-------------------------------------|-------------------------------------|------------------------|
| Escherichia spp. | Fecal swabs | Farm A (n = 13) | McC + COX | 13 (100%) | 0 (0%) | ND | 12 (92%) |
| Pseudomonas spp. | Raw milk filters | Farm B (n = 4) | CARBA | 0 (0%) | 4 (100%)c | 0 (0%) | 0 (0%) |
| | | Farm C (n = 2) | CARBA | 0 (0%) | 2 (100%)c | 0 (0%) | 0 (0%) |

n = isolates showing “microbiological” resistance to cefotaxime and isolated on McC + COX, or isolates showing “microbiological” resistance to imipenem and isolated on ChromID™ CARBA or OXA-48 were considered (see Materials and Methods); ND, non-determined.

a Isolates showing clavulanate synergy with cefotaxime, ceftazidime, cefepime or all compounds, suggesting the presence of an ESBL (independently of the presence of other mechanisms).
b Escherichia isolates showing “microbiological” resistance to cefoxitin (see Materials and Methods).
c Pseudomonas isolates showing ceftazidime inhibition with imipenem (see Materials and Methods).
d Based on a Rapideco CARBA NP test (see Materials and Methods).
e Based on the classification by Magiorakos et al. (50).

TABLE 4 | Resistance patterns of Escherichia strains isolated from dairy cows’ rectal swabs in Farm A (n = 13) on the basis of inhibition zone diameter breakpointsf.

| Resistance profile | No. of isolates with profile | % of isolates with profile | MDR statusg |
|--------------------|-----------------------------|---------------------------|-------------|
| AMP COX            | 1                           | 7.7%                       | Non-MDR     |
| AMP COX FEP TET    | 1                           | 7.7%                       | MDR         |
| AMP COX SXT TET    | 2                           | 15.4%                      | MDR         |
| AMP COX FEP TET SXT | 5                          | 38.5%                      | MDR         |
| AMP COX FEP SXT LHV | 1                         | 7.7%                       | MDR         |
| AMP COX FEP SXT CIP LHV | 2                        | 15.4%                      | MDR         |

f “Microbiological” resistance based on EUCAST ECOFF when available; EUCAST clinical breakpoint 2020 if not; CLSI 2018 if none available.
g Magiorakos et al. (50).
AMP, ampicillin; FEP, cefepime; COX, cefotaxime; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; CIP, ciprofloxacin; LHV, levofloxacin.

milk on carbapenem-supplemented media are often resistant to carbapenems because of non-CP resistance mechanisms, that can be either intrinsic to certain species (36, 42) or a combination of acquired resistance mechanisms in certain strains (57, 58).

The use of McC + COX media as an initial screening step for detection of ESBL-producing E. coli is fairly common as it allows a presumptive diagnosis of E. coli colonies based on their ability to ferment lactose, conferring them a typical pink color, even if there are some strains which ferment it slowly or not at all (59–61). In some studies [e.g., (12, 51, 62)], ESBL-producing E. coli have been searched for only among E. coli which formed typical lactose-positive colonies according to the “Materials and Methods” description. Yet in our study, lactose-negative ESBL-producing E. coli strains were isolated at a much higher frequency than lactose-positive strains (12 vs. 1) illustrating that failure to include these strains in monitoring programs could result in serious underestimation of ESBL prevalence among E. coli. This microbiological difference among ESBL-producing Escherichia strains isolated in spring/summer and in winter might be explained by a change of the dominant genotypes in the lactating dairy cows, as described in calf cohorts in a previous longitudinal study (63).

When monitoring healthy dairy cows we isolated with our protocol a majority of non-GN organisms in fecal swabs, especially Candida organisms. Among these non-GN strains, most of them (74 out of 93, all farms combined) were recorded at the second reading 36–48 h after inoculation and not at the first reading 18–24 h after inoculation. Therefore, suppressing the additional 18–24 h of inoculation would greatly restrict the isolation of non-GN organisms. On the other hand, this extra-step allowed for a better differentiation between strains when monitoring RMFs and permitted a more precise isolation of morphologically different colonies. If other protocols were to keep a 36–48 h incubation period with similar media we would recommend a gram-staining before any identification step so that non-GN organisms could be rapidly excluded.

By monitoring RMFs all year-long in Farms B and C, we detected the persisting presence of Pseudomonads. This observation is consistent with previous studies (64, 65). From a public health risk point of view, none of the IPM-strains were CP-producing, which means that resistance was most likely an association of non-horizontally-transferrable resistant mechanisms as is often described in P. aeruginosa (58, 66, 67) and that commercial carbapenem agars were not specific enough to differentiate these strains.

This is one of the few studies reporting monitoring of resistant bacteria at the herd level by using RMFs (33, 34) and performing a longitudinal monitoring of antimicrobial resistance in dairy farms (15, 63, 68–70) rather than a single snapshot. Our results are consistent with other European studies which failed to detect CP-producing strains in cattle but showed that ESBL-phenotypes were closely associated with MDR, especially to AMP-TET-STX (46). Our results also illustrate that ESBL-status in fecal swabs can change monthly in a positive-farm, therefore the terminology of Gonggrijp et al. (51) who defined herds that tested negative as “unsuspected” seems appropriate. This variation in status could be due to low sensitivity of our method and/or to an overall low prevalence of ESBL-producing GN enteric bacteria in the dairy
farms chosen in our study. Further research in other farms with different ESBL-/AmpC-/CP-statuses is needed to better assess the potential of analyzing RMF as a proxy for the dairy herd fecal contamination by resistant GN commensal bacteria. We believe monitoring CP-producing bacteria in dairy herds by using RMFs could be advantageous compared to fecal samplings, but is hindered by the lack of specificity of commercially available carbapenem-supplemented media when applied to dairy cattle.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

Ethical review and approval was not required for the animal study because no ethical review and approval required for this study where animal subjects were only submitted to a rectal swab. Written informed consent was obtained from the owners for the participation of their animals in this study.

AUTHOR CONTRIBUTIONS

SG and YM: conceptualization, validation, and supervision. VP and YM: investigation. PG, SG, and YM: resources. VP: writing—original draft preparation and visualization. PG and YM: writing—review and editing and funding acquisition. YM: project administration. All authors contributed to the article and approved the submitted version.

FUNDING

This research was funded by Ceva Santé Animale.

ACKNOWLEDGMENTS

Christelle Gandoin and Corinne Bouillin are gratefully acknowledged for their expert technical assistance during laboratory procedures.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fvets.2021.633598/full#supplementary-material

REFERENCES

1. Madec J-Y, Haenni M, Nordmann P, Poirel L. Extended-spectrum beta-lactamase/AmpC- and carbapenemase-producing Enterobacteriaceae in animals: a threat for humans. Clin Microbiol Infect. (2017) 23:826–33. doi: 10.1016/j.cmi.2017.01.013
2. Guerra B, Fischer J, Helmuth R. An emerging public health problem: acquired carbapenemase-producing microorganisms are present in food-producing animals, their environment, companion animals and wild birds. Vet Microbiol. (2014) 171:290–7. doi: 10.1016/j.vetmic.2014.02.001
3. Palmeira JD, Ferreira HMN. Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in cattle production - a threat around the world. Heliyon. 6 (2020) 6:1–20. doi: 10.1016/j.heliyon.2020.e03206
4. Adams RJ, Kim SS, Mollenkopf DE, Mathys DA, Schuenemann GM, Daniels JB, et al. Antimicrobial-resistant Enterobacteriaceae recovered from companion animal and livestock environments. Zoonoses Public Health. (2018) 65:519–27. doi: 10.1111/zph.12462
5. Diab M, Hamze M, Madec J-Y, Haenni M. High prevalence of Non-ST131 CTX-M-15-producing Escherichia coli in healthy cattle in Lebanon. Microb Drug Resist. (2016) 23:261–6. doi: 10.1089/mdr.2016.0019
6. Hartmann A, Locatelli A, Amoureux I, Depret G, Jolivet C, Gueneau E, et al. Occurrence of CTX-M-producing Escherichia coli in soils, cattle, and farm environment in France (Burgundy region). Front Microbiol. (2012) 3:83. doi: 10.3389/Fmicb.2012.00083
7. Madec J-Y, Lazizzera C, Châtre P, Munier D, Martin S, Lepage G, et al. Prevalence of fecal carriage of acquired expanded-spectrum cephalosporin resistance in Enterobacteriaceae strains from Cattle in France. J Clin Microbiol. (2008) 46:1566–7. doi: 10.1128/JCM.02299-07
8. Braun SD, Ahmed MFE, El-Adawy H, Hotzel H, Engelmann I, Weiss D, et al. Surveillance of extended-spectrum beta-lactamase-producing Escherichia coli in dairy cattle farms in the Nile delta, Egypt. Front Microbiol. (2016) 7:1020. doi: 10.3389/fmicb.2016.01020
9. Poirel L, Berço B, Millemenn Y, Bonnin R, Pannaux G, Nordmann P. Carbapenemase-producing Acinetobacter spp. in cattle. France. Emerg Infect Dis. (2012) 18:523–5. doi: 10.3201/eid1803.111330
10. Schmid A, Hörmandscher S, Messelhauser U, Käsböhrer A, Sauter-Louis C, Mansfeld R. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli on Bavarian dairy and beef cattle farms. Appl Environ Microb. (2013) 79:3027–32. doi: 10.1128/AEM.00204-13
11. Velasova M, Smith RP, Lemfa F, Horton RA, Duggett NA, Evans J, et al. Detection of extended-spectrum beta-lactam, AmpC and carbapenem resistance in Enterobacteriaceae in beef cattle in Great Britain in 2015. J Appl Microbiol. (2019) 126:1081–95. doi: 10.1111/jam.14121
12. Heuvelink AE, Gonggrijp MA, Buter RJG, ter Bogt-Kappert CC, Van Schaik G, Velhuis AGJ, et al. Prevalence of extended-spectrum and AmpC beta-lactamase-producing Escherichia coli in Dutch dairy herds. Vet Microbiol. (2019) 232:58–64. doi: 10.1016/j.vetmic.2019.04.005
13. Hille K, Ruddat I, Schmid A, Herent J, Hartmann M, Von Münchhausen C, et al. Cefotaxime-resistant E. coli in dairy and beef cattle farms - Joint analyses of two cross-sectional investigations in Germany. Prev Vet Med. (2017) 142:39–45. doi: 10.1016/j.prevetmed.2017.05.003
14. Ibrahim DR, Dodd CER, Stekel DJ, Ramsden SJ, Hobman JL. Multidrug resistant, extended spectrum beta-lactamase (ESBL)-producing Escherichia coli isolated from a dairy farm. FEMS Microbiol Ecol. (2016) 92:fw013. doi: 10.1093/femsec/fw013
15. Watson E, Jeckel S, Snow L, Stubs R, Teale C, Wearing H, et al. Epidemiology of extended spectrum beta-lactamase E. coli
definitions for acquired resistance. Clin Microbiol Infect. (2012) 18:268–81. doi: 10.1111/j.1469-0691.2011.03570.x

51. Gonggrijp MA, Santman-Berends IMGA, Heuvelink AE, Bouter GJ, Van Schaik G, Hage JJ, et al. Prevalence and risk factors for extended-spectrum beta-lactamase- and AmpC-producing Escherichia coli in dairy farms. J Dairy Sci. (2016) 99:9901–13. doi: 10.3168/jds.2016-11134

52. Tello M, Ocejo M, Oporto R, Hurtado A. Prevalence of cefotaxime-resistant Escherichia coli isolated from healthy cattle and sheep in northern Spain: phenotypic and genome-based characterization of antimicrobial susceptibility. Appl Env Microb. (2020) 86:e00742–20. doi: 10.1128/AEM.00742-20

53. Al S, Hizlisoy H, Ertas Onmaz N, Karadal F, Barel M, Yildrim Y, et al. A molecular investigation of carbapenem-resistant Enterobacteriaceae and blaKPC, blaNDM and blaOXA-48 genes in raw milk. Kafkas Univ Vet Fak Derg. (2020) 26:391–6. doi: 10.9775/kvfd.2019.23329

54. Girlich D, Anglade C, Zambardi G, Nordmann P. Comparative evaluation of a novel chromogenic medium (chromID OXA-48) for detection of OXA-48 producing Enterobacteriaceae. Diagn Micro Infec Dis. (2013) 77:296–300. doi: 10.1016/j.diagmicrobio.2013.08.015

55. Papadimitriou-Olivergeris M, Bartzavali C, Christofidou M, Berekzi N, Hey J, Zambardi G, Nordmann P. Performance of ChromID CARBA medium for carbapenemase-producing enterobacteriaceae detection during rectal screening. Eur J Clin Microbiol Infect Dis. (2014) 33:35–40. doi: 10.1007/s10096-013-1925-6

56. Vrioni G, Daniil I, Voulgari E, Ranellou K, Koumaki V, Ghirardi S, et al. Comparative evaluation of a prototype chromogenic medium (ChromID CARBA) for detecting carbapenemase-producing Enterobacteriaceae in surveillance rectal swabs. J Clin Microbiol. (2012) 50:1841–6. doi: 10.1128/JCM.06848-11

57. Cornaglia G, Hrynewicz W, Jarlier V, Kahlmeter G, Muttermayer H, Stratchounski L, et al. European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect. (2004) 10:349–83. doi: 10.1111/j.1198-743X.2004.00887.x

58. Rodriguez-Martinez J-M, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. (2009) 53:4783–8. doi: 10.1128/AAC.00574-09

59. Nicollotti M, Superti F, Conti C, Calconi A, Zagarla C. Virulence factors of lactose-negative Escherichia coli strains isolated from children with diarrhoea in Somalia. J Clin Microbiol. (1988) 1988:524–9. doi: 10.1128/JCM.26.3.524-529.1988

60. Sheddun WH, Potter CW, Dubowitz W, Wood M. An epidemic of gastroenteritis due to an uncommon variant of Escherichia coli 0128. J Clin Pathol. (1962) 15:482–3. doi: 10.1136/jcp.15.5.482

61. Yaratha G, Perloff S, Changada K. Lactose vs non-lactose fermenting E. coli: epidemiology, clinical outcomes, and resistance. Open Forum Infect Dis. (2017) 4(Suppl. 1):S589–90. doi: 10.1093/ofid/ofx163.1.5416

62. Santman-Berends IMGA, Gonggrijp MA, Hage JJ, Heuvelink AE, Velthuis A, Lam TJGM, et al. Prevalence and risk factors for extended-spectrum beta-lactamase or AmpC-producing Escherichia coli in organic dairy herds in the Netherlands. J Dairy Sci. (2017) 100:562–71. doi: 10.3168/jds.2016-11839

63. Hoyle DV, Davison HC, Knight HI, Yates CM, Dobay O, Gunn GJ, et al. Short communication: molecular characterisation of bovine faecal Escherichia coli shows persistence of defined ampicillan resistant strains and the presence of class 1 integrons on an organic beef farm. Vet Microbiol. (2006) 115:250–7. doi: 10.1016/j.vetmic.2006.01.006

64. Leriche F, Fayolle K. No seasonal effect on culturable pseudomonads in fresh milks from cattle herds. J Dairy Sci. (2012) 95:2999–306. doi: 10.3168/jds.2011-4785

65. Nucera DM, Lomonaco S, Morra P, Ortoffi FM, Giaccone D, Grassi MA. Dissemination and persistence of Pseudomonas spp. in small-scale dairy farms. Ital J Food Saf. (2016) 5:5652–5. doi: 10.4081/ijfs.2016.5.5652

66. Listor PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. (2009) 22:582–610. doi: 10.1128/CMR.00040-09

67. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. (2006) 50:1633–41. doi: 10.1128/AAC.50.5.1633-1641.2006

68. Awosile B, McClure J, Sanchez J, Rodriguez-Lecompte JC, Keefe G, Heider LC. Salmonella enterica and extended-spectrum cephalosporin-resistant Escherichia coli recovered from Holstein dairy calves from 8 farms in New Brunswick, Canada. J Dairy Sci. (2018) 101:3271–84. doi: 10.3168/jds.2017-13277

69. Horton RA, Duncan D, Randall LP, Chappell S, Brunton LA, Warner R, et al. Longitudinal study of CTX-M ESBL-producing E. coli strains on a UK dairy farm. Res Vet Sci. (2016) 109:107–13. doi: 10.1016/j.rsvet.2016.09.018

70. Liebana E, Batchelor M, Hopkins KL, Clifton-Hadley FA, Teale CJ, Foster A, et al. Longitudinal farm study of extended-spectrum-beta-lactamase-mediated resistance. J Clin Microbiol. (2006) 44:1630–4. doi: 10.1128/JCM.44.5.1630-1634.2006

Conflict of Interest: The authors declare that this study received funding from Ceva Santé Animale. The funder had the following involvement in the study: writing - review and editing. In all the other aspects of the study - design, collection, analysis, interpretation of data and decision to submit it for publication - the authors declare that the funder was not involved.

Copyright © 2021 Plassard, Gisbert, Granier and Millemann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.